Nick McCookeis Chief Business Officer of
DNA Electronics. He is an experienced and successful bio-entrepreneur,
well-known for leading the Solexa team that built the Next Generation
Sequencing(NGS) platform that became the basis of Illumina’s current
market-leading product line.
Previously, Nick was a consultant in the
biotechnology industry, working primarily in the areas of NGS and biomarkers.
In particular, he was recently interim COO of Cambridge Epigenetix, the
Syncona-funded Cambridge University start-up, coordinating the launch, in
August 2013, of their first product in the NGS space. Before that he was
part-time CEO of Oxford Cancer Biomarkers for about 18 months from start-up,
where he inked a key collaborative deal for the company with Astra Zeneca. Earlier
he was CEO of Belgium-based Pronotanv, a company discovering novel protein
biomarkers of disease in blood and developing them as diagnostic tests.
Nick joined Solexa as CEO in 2000, and led
it through the development of its game-changing DNA sequencing technology to
its listing on NASDAQ.
Apart from his base in the UK, Nick has
lived and worked in the USA, Japan and Belgium. He is a non-executive director
of AIM-listed biotech company Bioventix PLC and from June 2014, a trustee of
the Association of Medical Research Charities. He has an MBA from the London